Specialty Pharmacy

Majority of older patients with cancer and those who survived the disease found to have high levels of social and psychological wellbeing.

A pair of new studies is shedding light on a rare, but scientifically important, group of people with HIV who are able to maintain viral control even after stopping antiretroviral therapy.

Officials with Gilead Sciences, Inc. plan to launch authorized generic versions of Epclusa and Harvoni.

The US Preventive Services Task Force recommends against routine screening for prostate cancer in men 70 years of age and older.

In this clip, Gordon Vanscoy, PharmD, MBA, CEO of PANTHERx Specialty Pharmacy, explains how orphan drugs are making an impact on patients in the era of precision medicine.

Financial modeling tool shows research and development lacking of new vaccine candidates for HIV, tuberculosis, and malaria.

By mapping out the epigenomic landscape of rheumatoid arthritis, scientists hope to gain insight on disease origins as well as new cell signaling pathways.

The CLL/SLL indication is a standard approval and the follicular lymphoma indication is an accelerated approval contingent on the results of a confirmatory trial

A mobile app technology used to identify and track symptom relief helped measure real-time cannabis use.

Diets high in foods such as vegetables, fruit, and healthy fats found to lower the risk of death from all causes, cardiovascular disease, and cancer.

The American Hospital Association (AHA) and individual hospitals have initiated new principles for ensuring good stewardship of the 340B drug program.

A new report has found mortality rates for 5 of the 12 leading causes of death in the United States have increased since 2000.

A national survey demonstrated gaps in medical providers’ knowledge about changes to HIV health care delivery due to the Affordable Care Act.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

The FDA did not identify any new or unexpected safety findings with pimavanserin (Nuplazid), nor findings that are inconsistent with the established safety profile currently described in the drug label.

Phase 3 trial results for dupilumab (Dupixent) demonstrate improvement in skin clearing, itch, and certain quality of life measurements for adolescents with atopic dermatitis.

The phase 3 PARADIGMS clinical trial is the first-ever study designed for children and adolescents aged 10 to 17 years old with relapsing forms of multiple sclerosis.

Top news of the day from across the health care landscape.

Patients with multiple sclerosis incur higher costs and experience lower health-related quality of life as their disability increases

Deaths due to poor-quality health care represent a substantial challenge for universal coverage in low- and middle-income countries.

Top news of the day from across the health care landscape

Sequential administration of HER2+ therapy and chemotherapy did not affect survival outcomes in patients with breast cancer.

Study establishes real-world efficacy, tolerability, and safety profile of sofosbuvir-based regimens in patients with chronic hepatitis C who have compensated liver cirrhosis.

The Patient Right to Know Drug Prices Act would prohibit insurers and prescription benefit managers from using gag clauses by health insurers and pharmacy benefit managers.

The National Comprehensive Cancer Network updated its Clinical Practice Guidelines for kidney cancer to include new recommendations for cabozantinib tablets.

Tildrakizumab (Ilumetri) received approval by the European Commission for the treatment of moderate-to-severe chronic plaque psoriasis.